While there are RNAi products on the marketplace, with Alnylam becoming the first company to get a product approved in 2018, it is difficult to get this class of drug distributed through the brain ...

RNA interference (RNAi) therapeutics silence genes, disrupting the production of proteins that contribute to disease. Scientists at Alnylam Pharmaceuticals have developed and are testing multiple RNAi ...

In 2002, on the heels of the discovery that RNA interference existed in human cells, the usually reserved journal Science proclaimed RNAi the "breakthrough of the year." Here was a part of the ...

RNAi therapeutics have shown great success with multiple US Food and Drug Administration (FDA)-approved products involving N-acetyl galactosamine (GalNAc)-conjugated siRNAs to treat liver-targeted ...

Chief executive officer John Maraganore said that if regulatory reviews go well, Alnylam could have four RNAi products on the market by the end of next year. The company is also conducting ...

BOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the completion of a $97 ...

View Full Profile. Learn about our Editorial Policies. The natural RNAi mechanism can be directed by either short interfering RNA (siRNA) or microRNA (miRNA). 1 There are four key steps in the RNAi ...